Table 1 Summary of the clinical trials that used pirfenidone for fibrosis-related diseases
From: The multifaceted role of pirfenidone and its novel targets
Disease | Dose and time | Type of study | Number of patient | Effects | Reference |
|---|---|---|---|---|---|
Interstitial pulmonary fibrosis | 3600 mg/daily for 2 years | Open-label study | 54 | Increase in 1 and 2 year survival. Stabilized lung function. | [42] |
Interstitial pulmonary fibrosis | 600 mg three times daily for 12 months | Double-blind, randomized, placebo- controlled trial | 107 | Improvement in SpO2 during a 6-minute exercise test. No episodes of acute exacerbation of IPF in PFD group. | [43] |
Hermansky-Pudlak syndrome | 800 mg three times daily for 44 months | Randomized, placebo-controlled trial | 11 | Loss of pulmonary functions occurred at a slower rate. | [44] |
HCV related liver disease | 1200 mg/daily for 12 months | Open-label pilot study | 15 | 30% of patients had less fibrosis after treatment. Downregulation of Col I, TGFβ and TIMP-1. Improvement in quality of life (SF-36 test). | [55] |
Focal segmental glomerulosclerosis | 800 mg three times daily for 5 to 37 months | Open-label pilot study | 18 | Slowed renal function decline; improvement of 25% | [67] |
Hypertropic scars | PFD 8% gel for 6 months | Open-label pilot study | 33 | Improvement in the Vancouver scar score in 66.6% of patients. | [70] |